New hope for kids with rare muscle disease: zilucoplan safety trial launches
NCT ID NCT06435312
First seen Dec 26, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This study looks at the long-term safety of a daily injection called zilucoplan in children with a rare autoimmune disease that causes muscle weakness. Up to 8 children who completed a previous study will receive the drug for another 52 weeks. The goal is to monitor side effects and see how the body processes the medicine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mg0015 20104
Seoul, South Korea
-
Mg0015 20220
Seoul, South Korea
-
Mg0015 40144
Milan, Italy
-
Mg0015 40218
Warsaw, Poland
-
Mg0015 40735
Glasgow, United Kingdom
-
Mg0015 40736
London, United Kingdom
-
Mg0015 40774
Katowice, Poland
Conditions
Explore the condition pages connected to this study.